A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
BACKGROUND: Emerging data on cardiovascular outcomes, specifically major adverse cardiovascular events (MACE), are being reported from various trials involving incretin mimetics, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and glucos…
PURPOSE OF REVIEW: This review summarizes key findings from cardiovascular disease prevention studies presented at the 2025 European Society of Cardiology (ESC) Conference. It highlights trials on novel therapies, vaccination, blood pressure manageme…
Obesity and related conditions are associated with distressing food preoccupation that often culminates in dysregulated eating behaviors. Incretin-based therapies can reduce excessive weight in obesity, but their impact on dysregulated eating behavio…
AIMS: We investigated changes in eating behavior associated with the administration of tirzepatide and evaluated any changes in diet-related QOL due to tirzepatide. METHODS: The study included 60 outpatients with type 2 diabetes mellitus who had been…
BACKGROUND: Obstructive sleep apnea (OSA) is a common condition characterized by repeated airway collapse during sleep, leading to breathing interruptions. OSA increases the risk of developing hypertension, heart disease, stroke, and respiratory comp…
The field of antiobesity pharmacotherapy is rapidly evolving. FDA-approved medications, such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide, have significantly improved weight-loss outcomes. Agents such as semaglutide and…
ABSTRACT: Glucagon-Like- Peptide-1 (GLP-1) receptor agonist has an emerging role in obesity management. This meta-analysis and systematic review evaluated the effectiveness of GLP-1 receptor agonists in aiding weight loss and enhancing cardiometaboli…
Parkinson's disease (PD) is an age-related progressive disorder that leads to dopaminergic loss and subsequent motor dysfunction. Current therapies mainly deal with symptomatic effects, and hence, therapies targeting progressive neurodegeneration nee…
OBJECTIVE: To describe seven cases of patulous Eustachian tube (PET, "Tuba aperta") arising in adult patients undergoing significant weight loss with GLP-1 receptor agonists (semaglutide [Ozempic] or tirzepatide [Mounjaro]). METHODS: Retrospective de…
BACKGROUND: Data on tirzepatide added to basal insulin in patients with type 2 diabetes in China are scarce. We aimed to evaluate the efficacy and safety of tirzepatide added to basal insulin in this population. METHODS: SURPASS-CN-INS was a 40-week,…
BACKGROUND: Tirzepatide has shown benefits in weight reduction and glycemic control in type 2 diabetes and obesity, but its relative efficacy and safety across doses remain unclear. METHODS: We conducted a PROSPERO-registered systematic review and ne…
BACKGROUND: Tirzepatide (TZP) has demonstrated efficacy for glycemic control and weight loss in subjects with type 2 diabetes (T2D). However, previous clinical trials were not conducted under the treatment of glucagon-like peptide-1 receptor agonists…
BACKGROUND: While cardiovascular benefits of tirzepatide, a glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes mellitus (T2DM), and its comparative effectiveness vs glucagon-like peptide…
AIM: Obesity is a global epidemic. The FDA has approved glucagon-like peptide-1 (GLP-1) receptor agonists such as Liraglutide, Semaglutide, and the GLP-1/gastric inhibitory polypeptide (GIP) dual agonist Tirzepatide for the treatment of obesity. Clin…
IMPORTANCE: Semaglutide and tirzepatide, the new generation of glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes and obesity, were recently reported to be associated with increased risk of nonarteritic anterior ischemic optic neu…
AIM: To assess the efficacy and safety of once-weekly tirzepatide in Japanese participants with obesity and type 2 diabetes (T2D). MATERIALS AND METHODS: This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the S…
OBJECTIVE: To characterize the tolerability associated with incretin analog interchanges to equipotent or higher strengths based on an interchange process in an adult outpatient setting. METHODS: This was a retrospective chart review of adult patient…